English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Zendy Plus

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Zendy Tools

Zendy Open

Rapamycin is applied after allogeneic bone marrow transplantation to attenuate the development of GVHD although the cellular targets of rapamycin treatment are not well defined. Here, we show for the first time that GVHD prophylaxis by rapamycin after allogeneic bone marrow transplantation increases the immunosuppressive capacity of MDSCs, while the functionality of T cells is not affected thereby preserving the GVT effect. Our data might have clinical implications by better understanding the action of rapamycin in the context of allogeneic stem cell transplantation and might be indicative for the clinical use of rapamycin in diseases where the immunosuppressive functions of MDSCs need to be strengthened without impairing T cell functions.

clinical & experimental immunology

Rapamycin‐based graft‐ versus ‐host disease prophylaxis increases the immunosuppressivity of myeloid‐derived suppressor cells without affecting T cells and anti‐tumor cytotoxicity